<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519788</url>
  </required_header>
  <id_info>
    <org_study_id>AT-301-AU-01</org_study_id>
    <nct_id>NCT04519788</nct_id>
  </id_info>
  <brief_title>AT-301 Nasal Spray in Healthy Adults</brief_title>
  <official_title>A Double-blinded, Randomised, and Placebo-controlled Safety Study of AT-301 Nasal Spray in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atossa Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atossa Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study.&#xD;
      The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part 1) followed&#xD;
      by a multiple ascending dose (MAD) part (Part 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Actual">January 12, 2021</completion_date>
  <primary_completion_date type="Actual">December 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>8 participants per cohort (randomised AT-301A/Placebo : AT-301B, 2:6). Part 1: (SAD) Participants will receive: Cohort 1 - AT- 301A/Placebo or AT-301B 0.1mL per nostril (0.2mL total); or, Cohort 2 - AT-301A/Placebo or AT-301B 0.2mL per nostril (0.4mL total).&#xD;
Part 2: (MAD) Cohort 3 - AT-301A/Placebo or AT-301B 0.1mL per nostril (0.2mL total), three times/day for 14 days; or, Cohort 4 - AT- 301A/Placebo or AT-301B) 0.2mL per nostril (0.4mL total), three times/day for 14 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac, pulmonary and hemodynamic parameters using 12-lead ECG</measure>
    <time_frame>from baseline through study completion, an average of 40 days</time_frame>
    <description>incidence of abnormal ECG Change from baseline in clinical laboratory parameters&#xD;
Change from baseline in vital signs parameters&#xD;
Change from baseline in 12-lead ECGs&#xD;
Change from baseline in physical examination findings including auscultation&#xD;
Change from baseline in oxygen saturation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>auscultation</measure>
    <time_frame>from baseline through study completion, an average of 40 days</time_frame>
    <description>incidence of abnormal sounds Change from baseline in clinical laboratory parameters&#xD;
Change from baseline in vital signs parameters&#xD;
Change from baseline in 12-lead ECGs&#xD;
Change from baseline in physical examination findings including auscultation&#xD;
Change from baseline in oxygen saturation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>determination of oxygen saturation levels</measure>
    <time_frame>from baseline through study completion, an average of 40 days</time_frame>
    <description>Incidence of abnormal oxygen saturation Change from baseline in clinical laboratory parameters&#xD;
Change from baseline in vital signs parameters&#xD;
Change from baseline in 12-lead ECGs&#xD;
Change from baseline in physical examination findings including auscultation&#xD;
Change from baseline in oxygen saturation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>haematology, coagulation and serum chemistry</measure>
    <time_frame>from baseline through study completion, an average of 40 days</time_frame>
    <description>incidence of abnormal ranges Change from baseline in clinical laboratory parameters&#xD;
Change from baseline in vital signs parameters&#xD;
Change from baseline in 12-lead ECGs&#xD;
Change from baseline in physical examination findings including auscultation&#xD;
Change from baseline in oxygen saturation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urinalysis</measure>
    <time_frame>from baseline through study completion, an average of 40 days</time_frame>
    <description>incidence of abnormal measures Change from baseline in clinical laboratory parameters&#xD;
Change from baseline in vital signs parameters&#xD;
Change from baseline in 12-lead ECGs&#xD;
Change from baseline in physical examination findings including auscultation&#xD;
Change from baseline in oxygen saturation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal Spray Attributes Questionnaire score</measure>
    <time_frame>from baseline through study completion, an average of 40 days</time_frame>
    <description>based on a scale of 0 to 6, for each immediate attribute assessed; 0 equals none, 3 equals severe for each question; lower scores have better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AE (bronchospasms)</measure>
    <time_frame>from baseline through study completion, an average of 40 days</time_frame>
    <description>AE monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AT-301B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AT-301B consists of edetate disodium, glyceryl monooleate, polysorbate 80, benzalkonium chloride, microcrystalline cellulose and sodium carboxymethylcellulose (vivapur), trisodium citrate dihydrate, and purified water (HCl to adjust pH to 5.0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-301A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AT-301A consists of sodium chloride, benzalkonium chloride and purified water (NaOH/HCl to adjust pH to 5.0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-301B</intervention_name>
    <description>Nasal Spray</description>
    <arm_group_label>AT-301B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-301A</intervention_name>
    <description>Nasal Spray</description>
    <arm_group_label>AT-301A</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Must have given written informed consent before any study-related activities are carried&#xD;
        out and must be able to understand the full nature and purpose of the trial, including&#xD;
        possible risks and adverse effects 2. Adult males and females, 18 to 64 years of age&#xD;
        (inclusive) at the screening visit 3. Are non-smokers (including tobacco, e-cigarettes and&#xD;
        marijuana) for a minimum of 1 month prior to the screening visit. Non-smokers with a&#xD;
        significant history of smoking (&gt; 5 pack years) are not eligible 4. Have a physically&#xD;
        normal nasal structure (minor septum deviation allowable) 5. Body mass index (BMI)&#xD;
        (calculated) within the range of 18 to 30 kg/m2 inclusive at the screening visit and prior&#xD;
        to dosing on Day 1 6. Medically healthy without clinically significant abnormalities in the&#xD;
        opinion of the investigator at the screening visit and prior to dosing on Day 1, including:&#xD;
&#xD;
          1. Physical examination without any clinically significant findings&#xD;
&#xD;
          2. Systolic blood pressure (BP) in the range of 90 to 140 mm Hg (inclusive) and diastolic&#xD;
             BP in the range of 50 to 90 mm Hg (inclusive) after at least 5 minutes in a seated&#xD;
             position&#xD;
&#xD;
          3. Heart rate (HR) in the range of 45 to 100 beats/min (inclusive) after at least 5&#xD;
             minutes rest in a semi-recumbent position&#xD;
&#xD;
          4. Normal body (tympanic) temperature (35.5 to 37.7°C, inclusive)&#xD;
&#xD;
          5. The 12-lead electrocardiogram (ECG), taken after the volunteer has been supine for at&#xD;
             least 5 minutes, must be within normal range (corrected QT interval [QTc] males ≤450&#xD;
             msec; females ≤470 msec) or with abnormalities that are not hazardous to the volunteer&#xD;
&#xD;
          6. No clinically significant findings in serum chemistry, haematology, coagulation and&#xD;
             urinalysis examinations (Note: assessed at screening only for eligibility) 7. Negative&#xD;
             cotinine, drug and alcohol tests at screening and prior to dosing on Day 1 8. Female&#xD;
             volunteers must:&#xD;
&#xD;
        a. Be of non-child-bearing potential i.e., have follicle-stimulating hormone levels &gt;40&#xD;
        IU/L at screening and be surgically sterilized (hysterectomy, bilateral salpingectomy,&#xD;
        bilateral oophorectomy at least 6 weeks before the Screening visit) or postmenopausal&#xD;
        (where postmenopausal is defined as no menses for 12 months without an alternative medical&#xD;
        cause), or b. If of childbearing potential, must have a negative pregnancy test at&#xD;
        Screening (blood test) and before the first study drug administration (pre-dose Day 1 urine&#xD;
        test). They must agree not to attempt to become pregnant, must not donate ova, and must&#xD;
        agree to use a highly effective contraceptive method in addition to having their male&#xD;
        partner use a condom (if not surgically sterilised) for penile-vaginal intercourse from&#xD;
        signing consent until at least 30 days after the last dose of study therapy (Appendix 3) 9.&#xD;
        Male volunteers, if not surgically sterilised, must agree not to donate sperm and if&#xD;
        engaging in sexual intercourse with a female partner who could become pregnant, must agree&#xD;
        to use a condom in addition to having the female partner use a highly effective&#xD;
        contraceptive method (Appendix 3) from signing the consent form until at least 90 days&#xD;
        after the last dose of study therapy (Note: male volunteers are not required to use&#xD;
        contraception with a partner of the same sex) 10. Have suitable venous access for blood&#xD;
        sampling 11. Willing and able to comply with the requirements of the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of the following based on self-report: of tuberculosis, asthma&#xD;
             (including childhood asthma), severe bronchial asthma, chronic obstructive pulmonary&#xD;
             disease, peptic ulcer or major pulmonary airway disease&#xD;
&#xD;
          2. Previous diagnoses of nasal polyps or any ear, nose and throat pathology deemed by the&#xD;
             Investigator to affect assessment of the investigational product&#xD;
&#xD;
          3. Active hay fever, rhinitis or cold&#xD;
&#xD;
          4. History or presence of significant cardiovascular, hepatic, renal, haematological,&#xD;
             gastrointestinal, endocrine, immunologic, dermatologic, neurological or psychiatric&#xD;
             disease, including any acute illness or surgery within the past three months&#xD;
             determined by the PI to be clinically significant&#xD;
&#xD;
          5. Known allergy to any of the formula components&#xD;
&#xD;
          6. Current obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar&#xD;
             proteinosis and allergic alveolitis caused by lung tumour&#xD;
&#xD;
          7. Positive serum pregnancy test for women of childbearing potential at the Screening&#xD;
             visit or positive urine pregnancy test with confirmatory serum pregnancy test prior to&#xD;
             dosing on Day 1&#xD;
&#xD;
          8. Females who are breastfeeding&#xD;
&#xD;
          9. Liver function test results (i.e., aspartate aminotransferase [AST], alanine&#xD;
             aminotransferase [ALT], and gamma-glutamyl transferase [GGT]) and total bilirubin &gt;&#xD;
             1.5 x fold above the upper limit of normal at the screening visit. Elevated total&#xD;
             bilirubin allowable if an isolated finding&#xD;
&#xD;
         10. Positive testing for active human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg), hepatitis C virus (HCV) antibodies, at the screening visit&#xD;
&#xD;
         11. Use of any prescription or over-the-counter medication (including nasal medication,&#xD;
             herbal products, diet aids, and hormone supplements) within 7 days or 5 half-lives of&#xD;
             the medication (whichever is longer) prior to the first study drug administration,&#xD;
             except for contraceptives for female participants of childbearing potential and&#xD;
             occasional use of paracetamol&#xD;
&#xD;
         12. Donation of blood or plasma within 30 days prior to randomization, or loss of whole&#xD;
             blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood&#xD;
             transfusion within 1 year of study enrolment&#xD;
&#xD;
         13. Participation in another investigational clinical trial within 30 days or 5 half-lives&#xD;
             (whichever is longer) in the case of an investigational drug prior to the first study&#xD;
             drug administration&#xD;
&#xD;
         14. Any other condition or prior therapy, which, in the opinion of the Investigator, would&#xD;
             make the volunteer unsuitable for this study, including unable to cooperate fully with&#xD;
             the requirements of the study protocol or likely to be non-compliant with any study&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Canny</last_name>
    <role>Study Chair</role>
    <affiliation>Bellberry Limited HREC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMAX Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

